Importantly, in a competitive transplant setting, depletion of Nestin+ cells during AML development selectively diminished the number of leukemic cells, while leaving normal hematopoiesis unaffected (Forte et al., 2020), which is one of the major challenges in the treatment of AML. The gene discussed is NES; the disease is acute myeloid leukemia.